Published 5 August 2002. doi:10.1084/jem.20011838
© Rockefeller University Press, 0022-1007/2002/8/359/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 3, August 5, 2002 359-368
The Hematopoietic Systemspecific Minor Histocompatibility Antigen HA-1 Shows Aberrant Expression in Epithelial Cancer Cells
Christoph A. Klein1,
Martina Wilke3,
Jos Pool3,
Corine Vermeulen3,
Els Blokland3,
Elke Burghart1,
Sabine Krostina1,
Nicole Wendler1,
Bernward Passlick2,
Gert Riethmüeller1 and
Els Goulmy3
1 Department of Immunology, Klinikum Innenstadt, Ludwig-Maximilians University, 80336 Munich, Germany
2 Chirurgische Klinik, Klinikum Innenstadt, Ludwig-Maximilians University, 80336 Munich, Germany
3 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
Address correspondence to Els Goulmy, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Phone: 31-71-526-1966; Fax: 31-71-521-6751; E-mail: E.A.J.M.Goulmy{at}lumc.nl
Allogeneic stem cell transplantation (SCT) can induce curative graft-versus-tumor reactions in patients with hematological malignancies and solid tumors. The graft-versus-tumor reaction after human histocompatibility leukocyte antigen (HLA)-identical SCT is mediated by alloimmune donor T cells specific for polymorphic minor histocompatibility antigens (mHags). Among these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here, we report on the HA-1 ribonucleic acid expression by microdissected carcinoma tissues and by single disseminated tumor cells isolated from patients with various epithelial tumors. The HA-1 peptide is molecularly defined, as it forms an immunogenic peptide ligand with HLA-A2 on the cell membrane of carcinoma cell lines. HA-1specific cytotoxic T cells lyse epithelial tumor cell lines in vitro, whereas normal epithelial cells are not recognized. Thus, HA-1specific immunotherapy combined with HLA-identical allogeneic SCT may now be feasible for patients with HA-1+ carcinomas.
Key Words: stem cell transplantation graft-versus-tumor carcinomas cytotoxic T cells minimal residual disease

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Spierings, E., Gras, S., Reiser, J.-B., Mommaas, B., Almekinders, M., Kester, M. G. D., Chouquet, A., Le Gorrec, M., Drijfhout, J. W., Ossendorp, F., Housset, D., Goulmy, E.
(2009). Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele. J. Immunol.
182: 4809-4816
[Abstract]
[Full Text]
-
Hambach, L., Ling, K.-W., Pool, J., Aghai, Z., Blokland, E., Tanke, H. J., Bruijn, J. A., Halfwerk, H., van Boven, H., Wieles, B., Goulmy, E.
(2009). Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood
113: 2715-2722
[Abstract]
[Full Text]
-
Kolb, H.-J.
(2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood
112: 4371-4383
[Abstract]
[Full Text]
-
Hambach, L., Vermeij, M., Buser, A., Aghai, Z., van der Kwast, T., Goulmy, E.
(2008). Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood
112: 1844-1852
[Abstract]
[Full Text]
-
Kawase, T., Akatsuka, Y., Torikai, H., Morishima, S., Oka, A., Tsujimura, A., Miyazaki, M., Tsujimura, K., Miyamura, K., Ogawa, S., Inoko, H., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T.
(2007). Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood
110: 1055-1063
[Abstract]
[Full Text]
-
Hartmann, C. H., Klein, C. A.
(2006). Gene expression profiling of single cells on large-scale oligonucleotide arrays. Nucleic Acids Res
34: e143-e143
[Abstract]
[Full Text]
-
Rice, J., Dunn, S., Piper, K., Buchan, S. L., Moss, P. A., Stevenson, F. K.
(2006). DNA Fusion Vaccines Induce Epitope-Specific Cytotoxic CD8+ T Cells against Human Leukemia-Associated Minor Histocompatibility Antigens.. Cancer Res.
66: 5436-5442
[Abstract]
[Full Text]
-
Carnevale-Schianca, F., Cignetti, A., Capaldi, A., Vitaggio, K., Vallario, A., Ricchiardi, A., Sperti, E., Ferraris, R., Gatti, M., Grignani, G., Rota-Scalabrini, D., Geuna, M., Fizzotti, M., Sangiolo, D., Sottile, A., De Rosa, G., Bucci, A. R., Lambertenghi-Deliliers, G., Benedetti, E., Nash, R., Aglietta, M.
(2006). Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood
107: 3795-3803
[Abstract]
[Full Text]
-
Mommaas, B., Stegehuis-Kamp, J. A., van Halteren, A. G., Kester, M., Enczmann, J., Wernet, P., Kogler, G., Mutis, T., Brand, A., Goulmy, E.
(2005). Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood
105: 1823-1827
[Abstract]
[Full Text]
-
Tykodi, S. S., Warren, E. H., Thompson, J. A., Riddell, S. R., Childs, R. W., Otterud, B. E., Leppert, M. F., Storb, R., Sandmaier, B. M.
(2004). Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens. Clin. Cancer Res.
10: 7799-7811
[Abstract]
[Full Text]
-
Akatsuka, Y., Nishida, T., Kondo, E., Miyazaki, M., Taji, H., Iida, H., Tsujimura, K., Yazaki, M., Naoe, T., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T.
(2003). Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens. JEM
197: 1489-1500
[Abstract]
[Full Text]
-
Barrett, A. J., Rezvani, K., Solomon, S., Dickinson, A. M., Wang, X. N., Stark, G., Cullup, H., Jarvis, M., Middleton, P. G., Chao, N.
(2003). New Developments in Allotransplant Immunology. ASH Education Book
2003: 350-371
[Abstract]
[Full Text]